Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study

Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. High...

Descripción completa

Detalles Bibliográficos
Autores principales: Beudeker, Boris J. B., Groothuismink, Zwier M. A., de Man, Robert A., Witjes, Caroline D. M., van der Eijk, Annemiek A., Boonstra, Andre, Sonneveld, Milan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756674/
https://www.ncbi.nlm.nih.gov/pubmed/32869922
http://dx.doi.org/10.1111/jvh.13394
Descripción
Sumario:Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence‐free survival in patients with early, but not advanced, stage HCC.

Ejemplares similares